We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Depressing Stress Signaling Increases Immune Activity

By LabMedica International staff writers
Posted on 12 Sep 2017
Image: A ribbon model of the beta-2 adrenergic receptor (Photo courtesy of Wikimedia Commons).
Image: A ribbon model of the beta-2 adrenergic receptor (Photo courtesy of Wikimedia Commons).
Cancer researchers evaluating the immune status of the tumor microenvironment found that CD8+ T-cell frequency and functional orientation were regulated by beta-2-adrenergic receptor (beta-AR) signaling and suggested using clinically available beta-blockers in patients to improve responses to immunotherapy.

Anticancer therapies designed to block “checkpoints” within the immune system do not work for all patients, and their efficacy in controlling tumors is often short-lived. To better understand these phenomena and to improve the performance of check point inhibitors, investigators at Roswell Park Cancer Institute (Buffalo, NY, USA) used three strategies: physiologic (manipulation of ambient thermal environment), pharmacologic (beta-blockers), and genetic (beta-2-adrenergic receptor knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models.

They reported in the August 17, 2017, online edition of the journal Cancer Research that reducing beta-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment. This immunologically enriched microenvironment displayed increased frequency of CD8+ T-cells with an effector phenotype and decreased expression of PD-1, in addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio. Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade.

In short, manipulating beta-adrenergic receptor signaling to regulate the immune status of the tumor microenvironment supported the strategic use of clinically available beta-blockers in patients to improve responses to immunotherapy.

“Our bodies respond to certain types of stress - such as fear and anxiety, heat, cold, pain, depression, and even attack by cancer cells - in the same way. We jump into "fight or flight" mode, and the sympathetic nervous system dials up the release of norepinephrine,” said senior author Dr. Elizabeth Repasky, professor of immunology at Roswell Park Cancer Institute. “For reasons that we do not entirely understand yet, prolonged exposure to these stressors often makes our immune cells much less effective. But we demonstrate here that beta blockers, by reducing adrenergic signaling, allow anti-tumor immune cells to become much stronger, and give immunotherapies, and in particular checkpoint inhibitors, a much better chance to work.”

Related Links:
Roswell Park Cancer Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Platelet Function Analyzer
PL-12

Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more